Corpus Intelligence IC Memo — ENCOMPASS HEALTH REHABILITATION HOSP 2026-04-26 09:09 UTC
IC Memo — ENCOMPASS HEALTH REHABILITATION HOSP
Investment Committee Memorandum | MA | 53 beds | Grade C | EBITDA uplift $2.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ENCOMPASS HEALTH REHABILITATION HOSP

CCN 223030 | HAMPDEN, MA | 53 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

ENCOMPASS HEALTH REHABILITATION HOSP is a 53-bed suburban community hospital in HAMPDEN, MA with $31.6M in net patient revenue and a 20.5% operating margin. The hospital serves a payer mix of 68.5% Medicare, 2.7% Medicaid, and 28.8% commercial.

Thesis: Turnaround. Our ML models identify $2.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 20.5% to 27.8% (+736bps).

Net Revenue HCRIS$31.6M
Current EBITDA COMPUTED$6.5M
Operating Margin COMPUTED20.5%
Occupancy HCRIS94.2%
Revenue / Bed COMPUTED$596K
Net-to-Gross HCRIS74.7%
Distress Probability ML45.0%

2. Market Context & Competitive Position

99
MA Hospitals
-12.2%
State Median Margin
25
Comparable Hospitals

MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of 20.5% places it above the state median. Among 25 size-comparable peers (26-106 beds), the median margin is -11.9%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (26-106), prioritizing same-state peers. 25 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ENCOMPASS HEALTH REHABILITATIO (Target)MA53$31.6M20.5%
DANA-FARBER CANCER INSTITUTEMA30$1.88B-35.1%
MASSACHUSETTS EYE AND EAR INFIMA41$263.9M-36.1%
NEW ENGLAND BAPTIST HOSPITALMA75$221.2M-4.6%
FALMOUTH HOSPITALMA81$172.1M-2.2%
BIDMC-MILTON HOSPITAL INCMA102$134.8M-11.4%
BETH ISRAEL DEACONESS HOSPITALMA58$131.9M-1.6%
BAYSTATE FRANKLIN MEDICAL CENTMA89$98.1M-23.1%
MARLBOROUGH HOSPITALMA67$94.2M-21.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$663K+210bp18mo
Cost to Collect4.5%2.5%$632K+200bp12mo
Denial Rate Reduction12.0%6.5%$625K+198bp12mo
A/R Days Reduction5200.0%3800.0%$384K+122bp9mo
Clean Claim Rate88.0%96.0%$20K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$663K
Cost to Collect
$632K
Denial Rate Reduction
$625K
A/R Days Reduction
$384K
Clean Claim Rate
$20K
Total EBITDA Uplift$2.3M
Current EBITDA$6.5M
+ RCM Uplift+$2.3M
Pro Forma EBITDA$8.8M
Current Margin20.5%
Pro Forma Margin27.8%
WC Released (1x)$1.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$10.0M$65.9M6.62x46.0%
Base (11x exit)10.0x11.0x$10.0M$75.8M7.61x50.1%
Bull Case9.0x11.0x$9.0M$86.7M9.67x57.4%
Bull (12x exit)9.0x12.0x$9.0M$97.2M10.85x61.1%
Bear Case11.0x10.0x$11.0M$51.1M4.66x36.1%
Bear (11x exit)11.0x11.0x$11.0M$59.7M5.46x40.4%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumHeavy Medicare dependenceMedicare comprises 68.5% of days; rate updates may lag inflation. Mitigant: CDI/CMI lever directly increases Medicare reimbursement

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 25 hospitals with 26-106 beds
  • Same-state prioritization (n=26)
  • Comp margins: P25=-18.2% / P50=-11.9% / P75=-1.7%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.